New Variants at 10q26 and 15q21 Are Associated with Aggressive Prostate Cancer in a Genome-wide Association Study from a Prostate Biopsy Screening Cohort

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2011 Dec 2

PMID 22130093

Citations 27

Authors

Robert K Nam

William Zhang

Katherine Siminovitch

Adam Shlien

Michael W Kattan

Laurence H Klotz

John Trachtenberg

Yan Lu

Jinyi Zhang

Changhong Yu

Ants Toi

D Andrew Loblaw

Vasundara Venkateswaran

Aleksandra Stanimirovic

Linda Sugar

David Malkin

Arun Seth

Steven A Narod

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify and examine polymorphisms of genes associated with aggressive and clinical significant forms of prostate cancer among a screening cohort.

Experimental Design: We conducted a genome-wide association study among patients with aggressive forms of prostate cancer and biopsy-proven normal controls ascertained from a prostate cancer screening program. We then examined significant associations of specific polymorphisms among a prostate cancer screened cohort to examine their predictive ability in detecting prostate cancer.

Results: We found significant associations between aggressive prostate cancer and five single nucleotide polymorphisms (SNPs) in the 10q26 (rs10788165, rs10749408, and rs10788165, p value for association 1.3 × 10(-10 ) to 3.2 × 10(-11) ) and 15q21 (rs4775302 and rs1994198, p values for association 3.1 × 10(-8 ) to 8.2 × 10(-9)) regions. Results of a replication study done in 3439 patients undergoing a prostate biopsy, revealed certain combinations of these SNPs to be significantly associated not only with prostate cancer but with aggressive forms of prostate cancer using an established classification criterion for prostate cancer progression (odds ratios for intermediate to high-risk disease 1.8-3.0, p value 0.003-0.001). These SNP combinations were also important clinical predictors for prostate cancer detection based on nomogram analysis that assesses prostate cancer risk.

Conclusions: Five SNPs were found to be associated with aggressive forms of prostate cancer. We demonstrated potential clinical applications of these associations.

Citing Articles

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.

Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J Int J Mol Sci. 2023; 24(16).

PMID: 37628978 PMC: 10454494. DOI: 10.3390/ijms241612797.

Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease.

Saunders E, Kote-Jarai Z, Eeles R Cancers (Basel). 2021; 13(4).

PMID: 33673083 PMC: 7917798. DOI: 10.3390/cancers13040760.

α-lipoic acid protects testis and epididymis against linuron-induced oxidative toxicity in adult rats.

Prathima P, Venkaiah K, Daveedu T, Pavani R, Sukeerthi S, Gopinath M Toxicol Res. 2020; 36(4):343-357.

PMID: 33005594 PMC: 7494705. DOI: 10.1007/s43188-019-00036-y.

Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.

Tan S, Petrovics G, Srivastava S Int J Mol Sci. 2018; 19(4).

PMID: 29690565 PMC: 5979433. DOI: 10.3390/ijms19041255.

Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

Nowinski S, Santaolalla A, OLeary B, Loda M, Mirchandani A, Emberton M Oncotarget. 2018; 9(16):12812-12824.

PMID: 29560112 PMC: 5849176. DOI: 10.18632/oncotarget.24400.

References

Eeles R, Durocher F, Edwards S, TEARE D, Badzioch M, Hamoudi R . Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet. 1998; 62(3):653-8. PMC: 1376940. DOI: 10.1086/301745. View

Kraft P, Wacholder S, Cornelis M, Hu F, Hayes R, Thomas G . Beyond odds ratios--communicating disease risk based on genetic profiles. Nat Rev Genet. 2009; 10(4):264-9. DOI: 10.1038/nrg2516. View

Wiklund F, Adami H, Zheng S, Stattin P, Isaacs W, Gronberg H . Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev. 2009; 18(5):1659-62. PMC: 3353269. DOI: 10.1158/1055-9965.EPI-08-1148. View

Presti Jr J . Prostate biopsy strategies. Nat Clin Pract Urol. 2007; 4(9):505-11. DOI: 10.1038/ncpuro0887. View

Gudmundsson J, Sulem P, Manolescu A, Amundadottir L, Gudbjartsson D, Helgason A . Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007; 39(5):631-7. DOI: 10.1038/ng1999. View

Kader A, Sun J, Isaacs S, Wiley K, Yan G, Kim S . Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009; 69(11):1195-205. PMC: 2852875. DOI: 10.1002/pros.20970. View

Lohmueller K, Pearce C, Pike M, Lander E, Hirschhorn J . Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003; 33(2):177-82. DOI: 10.1038/ng1071. View

Yeager M, Orr N, Hayes R, Jacobs K, Kraft P, Wacholder S . Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007; 39(5):645-9. DOI: 10.1038/ng2022. View

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

10.

Nam R, Zhang W, Trachtenberg J, Seth A, Klotz L, Stanimirovic A . Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res. 2009; 15(5):1787-93. DOI: 10.1158/1078-0432.CCR-08-1593. View

11.

Kraft P . Curses--winner's and otherwise--in genetic epidemiology. Epidemiology. 2008; 19(5):649-51. DOI: 10.1097/EDE.0b013e318181b865. View

12.

Nam R, Toi A, Trachtenberg J, Jewett M, Klotz L, Fleshner N . Variation in patterns of practice in diagnosing screen-detected prostate cancer. BJU Int. 2004; 94(9):1239-44. DOI: 10.1111/j.1464-410X.2004.05150.x. View

13.

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148(5):1549-57; discussion 1564. DOI: 10.1016/s0022-5347(17)36966-5. View

14.

Price A, Patterson N, Plenge R, Weinblatt M, Shadick N, Reich D . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38(8):904-9. DOI: 10.1038/ng1847. View

15.

Chernova O, Hunyadi A, Malaj E, Pan H, Crooks C, Roe B . A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells. Oncogene. 2001; 20(38):5378-92. DOI: 10.1038/sj.onc.1204694. View

16.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

17.

Zheng S, Sun J, Wiklund F, Smith S, Stattin P, Li G . Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008; 358(9):910-9. DOI: 10.1056/NEJMoa075819. View

18.

Penney K, Salinas C, Pomerantz M, Schumacher F, Beckwith C, Lee G . Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009; 15(9):3223-30. PMC: 2878092. DOI: 10.1158/1078-0432.CCR-08-2733. View

19.

GLEASON D, MELLINGER G . Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974; 111(1):58-64. DOI: 10.1016/s0022-5347(17)59889-4. View

20.

Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L . The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003; 349(3):215-24. DOI: 10.1056/NEJMoa030660. View